Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Virtual Plenary: March 2022

ESMO-Virtual-Plenary-March-2022-1000x250
Start date
16 Mar 2022
End date
18 Mar 2022

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

Wednesday, 16 March 2022

Thursday, 17 March 2022

18:30-19:30 CET

13:00-14:10 CET / 20:00-21:10 SGT

Welcome and introduction, Scientific background and context
Thomas Helleday, Karolinska Institutet, Stockholm, Sweden

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Andrew Tutt, The Institute of Cancer Research, London, UK

Critical analysis and perspectives
Mark Robson, MSKCC - Memorial Sloan Kettering Cancer Center, New York, NY, USA

Live Discussion and Q&A (i)

Virtual Plenary Expert Insights: webcast of 16 March OlympiA presentation + Live Discussion and Q&A (ii)

Chair: Rebecca Dent, NCCS - National Cancer Centre Singapore, Singapore

Andrew Tutt, The Institute of Cancer Research, London, UK

Mark Robson, MSKCC - Memorial Sloan Kettering Cancer Center, New York, NY, USA

Nadia Harbeck, LMU Klinikum der Universität München, Munich, Germany

Ava Kwong, The University of Hong Kong, Hong Kong, China

Kelly-Anne Phillips, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Thursday, 17 March 2022

Friday, 18 March 2022

18:00-19:00 CET

11:45-12:55 CET / 18:45-19:55 SGT

Welcome and introduction, Scientific background and context
Isabelle Ray-Coquard, Centre Léon Bérard, Lyon, France

Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
Ignace Vergote, Leuven University Hospitals, Leuven, Belgium

Critical analysis and perspectives
Amit Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada

Live Discussion and Q&A (i)

Virtual Plenary Expert Insights: webcast of 17 March SIENDO presentation + Live Discussion and Q&A (ii)

Chair: Clare Scott, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Ignace Vergote, Leuven University Hospitals, Leuven, Belgium

Amit Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada

Sudeep Gupta, Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, India

Byoung-Gie Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

Thursday, 17 March 2022

Friday, 18 March 2022

19:15-20:15 CET

13:15-14:25 CET / 20:15 - 21:25 SGT

Welcome and introduction, Scientific background and context
Heather Wakelee, Stanford Cancer Institute, Stanford, CA, USA

Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain

Critical analysis and perspectives
Martin Reck, Lungen Clinic Grosshansdorf, Grosshansdorf, Germany

Live Discussion and Q&A (i)

Virtual Plenary Expert Insights: webcast of 17 March PEARLS/KEYNOTE-091 presentation + Live Discussion and Q&A (ii)

Chair: Ben Solomon, Peter MacCallum Cancer Center, Melbourne, VIC, Australia

Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain

Martin Reck, Lungen Clinic Grosshansdorf, Grosshansdorf, Germany

Keunchil Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Yi-Long Wu, Guangdong Province People's Hospital, Guangzhou, China

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.